Bio-identical
Hormones Market, By Product Type (Estrogen, Progesterone, and
Testosterone), By Dosage Form (Tablets and Capsules, Creams and Gels,
Injectable, Patches and Implants, and Others), By End User (Hospitals, Clinics,
Academics and Research Institutes, and Others), and By Region (North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share,
Outlook, and Opportunity Analysis, 2019 - 2027
Bio-identical hormones are
biochemically engineered hormones that resemble hormones produced by the human
body through natural biological processes. Estrogen, progesterone and
testosterone are some of the common hormones that are manufactured artificially.
Levels of hormones such as
estrogen, progesterone and testosterone in the body are lowered with
progression in age, which leads to certain menopausal symptoms in females such
as hot flashes, weight gain, and vaginal pain due to sexual intercourse, vaginal
dryness, night sweats, mood swings. In men, low testosterone level can cause
erectile dysfunction and reduced bone density. Bio-identical hormones are used
to treat men and women whose natural hormones levels are low or imbalanced. The
bio-identical hormones act as a replacement for natural hormones and increase
the hormonal levels in the body. This process is called bio-identical hormone
replacement therapy (BHRT). Bio-identical hormones are available in the form of
pills, creams, patches, gels, injectables, and implants.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3293
Global Bio-identical Hormones
Market – Dynamics
Factors such as increasing
geriatric population and females in the menopausal age group are expected to
boost the growth of the bio-identical hormones market over the forecast period.
For instance, according to an article published in the National Center for
Biotechnology Information (NCBI) in November 2019, nearly 1.3 million women
become menopausal every year in the U.S and around 75% of the females
experience vasomotor symptoms such as hot flashes, palpitations and night
sweating due to menopause.
In addition to the aforementioned
factors, rising awareness about the bio-identical hormone replacement therapy
(BHRT), coupled with increased screening of hormonal deficiency is projected to
propel the market growth over the forecast period. For instance, according to a
study conducted by researchers from the Obstetrics and Gynecology Department of
Kafkas University in January 2019, in Turkey, nearly 432 females out of 926
opted for bio-identical hormone replacement therapy in order to treat their
menopausal symptoms.
However, an increased risk of
breast cancer in females opting for bio-identical hormone therapy is expected
to restrain the market over the forecast period. For instance, according to a
study published in The Lancet journal, September 2019, nearly 108,647
postmenopausal women developed breast cancer, from 1992 to 2018, among these
approximately 55,575 females were using the hormonal therapy.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/bio-identical-hormones-market-3293
Global Bio-identical Hormones
Market – Regional Insights
North America accounted for the
largest market share in 2018 owing to launches and approvals of bio-identical
hormones in the region. For instance, in September 2018, TherapeuticsMD, Inc.,
a pharmaceutical company, launched Imvexxy, (estradiol vaginal inserts) in the
U.S. Imvexxy is used for treating moderate-to-severe dyspareunia (vaginal pain
associated with sexual activity), due to menopause. Moreover, in June 2019,
TherapeuticsMD, Inc. announced a license and supply agreement with Theramex, a
pharmaceutical company dedicated to women’s health, to commercialize IMVEXXY
(estradiol vaginal inserts) and BIJUVA (estradiol and progesterone capsules)
outside of the U.S., except in Canada and Israel.
Global Bio-identical Hormones
Market – Competitive Landscape
Key players operating in the
market are TherapeuticsMD, Inc., BioTE Medical, Defy Medical, Full Life
Wellness Center, Neuva Aesthetics, and SottoPelle.
Moreover, key players in the
market are focused on developing new products in order to enhance their market
share. For instance, in October 2018, TherapeuticsMD, Inc. received U.S. Food
and Drug Administration (FDA) approval for its first bio-identical hormone
combination therapy of estradiol and progesterone, BIJUVA. The oral capsule is
used for treatment of moderate to severe vasomotor symptoms due to menopause in
women.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3293
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment